US SB378 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Democrat 6-0)
Status: Introduced on February 7 2019 - 25% progression, died in committee
Action: 2019-02-07 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 7 2019 - 25% progression, died in committee
Action: 2019-02-07 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Imposes an excise tax on pharmaceutical companies that sell prescription drugs that are subject to price spikes that exceed the annual percentage increase in the Chained Consumer Price Index. For each taxable prescription drug, the excise tax ranges from 50% to 100% of price spike revenue received by the company, depending on the size of the price spike and including an adjustment for revenue that is due solely to an increase in the cost of the inputs necessary to manufacture the drug. Pharmaceutical companies must submit specified data regarding drug prices and revenue to the Inspector General (IG) of the Department of Health and Human Services (HHS), and the IG must submit an assessment of the data to the Internal Revenue Service. HHS, upon the recommendation of the IG, may exempt certain drugs from the excise tax if (1) a for-cause price increase exemption should apply; or (2) the drug has an average manufacturer price of not greater than $10 for a 30-day supply and is marketed by at least 3 other holders of applications approved under the Federal Food, Drug, and Cosmetic Act. The Government Accountability Office must examine (1) how drug manufacturers and health plans establish initial launch prices for newly approved drugs, and (2) alternative methods that have been proposed for setting the price of new drugs.
Title
Stop Price Gouging Act
Sponsors
Sen. Sherrod Brown [D-OH] | Sen. Kirsten Gillibrand [D-NY] | Sen. Margaret Hassan [D-NH] | Sen. Richard Blumenthal [D-CT] |
Sen. Tina Smith [D-MN] | Sen. Chris Van Hollen [D-MD] |
History
Date | Chamber | Action |
---|---|---|
2019-02-07 | Senate | Read twice and referred to the Committee on Finance. |
Same As/Similar To
HB1093 (Same As) 2019-02-07 - Referred to the Subcommittee on Health.
SB1801 (Related) 2019-06-12 - Read twice and referred to the Committee on Finance.
SB1801 (Related) 2019-06-12 - Read twice and referred to the Committee on Finance.
Subjects
Business records
Congressional oversight
Government information and archives
Government studies and investigations
Health care costs and insurance
Inflation and prices
Prescription drugs
Sales and excise taxes
Taxation
Congressional oversight
Government information and archives
Government studies and investigations
Health care costs and insurance
Inflation and prices
Prescription drugs
Sales and excise taxes
Taxation
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/senate-bill/378/all-info |
Text | https://www.congress.gov/116/bills/s378/BILLS-116s378is.pdf |